论文部分内容阅读
骨髓增生异常综合征(MDS)是一组具有某些类似血液学特点的恶性疾病,约20-38%可演变为急性白血病(AL),约20-40%可直接死于感染或严重出血,约45-72%在确诊后2年内死亡。中位生存期(MST)为475-636天。目前主张对极可能转化为AL或病情进展迅速者应采用化疗,而对病情相对呈良性者则应采用诱导分化及支持疗法。故在确诊MDS的同时,对患者作出转归及预后的预测,对指导治疗有一定的参考价值。本文拟就这一问题综述如下。影响预后的因素分析
Myelodysplastic syndrome (MDS) is a group of malignant diseases that have some similar hematological characteristics. About 20-38% can evolve to acute leukemia (AL), about 20-40% can die directly from infection or severe bleeding, About 45-72% died within 2 years after diagnosis. Median survival (MST) was 475-636 days. Currently advocated for the possibility of conversion to AL or rapid progression should be used chemotherapy, while the disease is relatively benign should be used to induce differentiation and supportive therapy. Therefore, in the diagnosis of MDS at the same time, patients with prognosis and outcome and prognosis, the guidance of treatment has a certain reference value. This article intends to summarize this issue as follows. Factors Influencing Prognosis